What happened According to a recent SEC filing, Nan Fung Group Holdings Ltd reduced its position in Oculis (NASDAQ:OCS) by 163,957 shares during the first quarter of 2026.
The estimated value of the trade was $4.3 million, based on the quarter’s average closing price
What else to know – Nan Fung’s remaining Oculis stake of 350,745 shares was valued at $9.3 million at quarter-end, representing 7.7% of the fund’s total AUM and ranking as its fourth-largest holding. – Top holdings after the filing: – NYSE: EVMN: $33.1 million (27.3% of AUM) – NASDAQ: MPLT: $19.7 million (16.3% of AUM) – NASDAQ: LBRX: $15.6 million (12.8% of AUM) – NASDAQ: OCS: $9.3 million (7.7% of AUM) – NASDAQ: INCY: $5.1 million (4.2% of AUM) – – As of June 5, 2026, Oculis shares were trading at $11.21 — down about 43% over the past year, and underperforming the S&P 500 by roughly 67 percentage points. Company overview Company snapshot Oculis Holding AG is a clinical-stage biopharmaceutical company developing novel topical therapies for ophthalmic and neuro-ophthalmic diseases. – Oculis targets ophthalmologists and healthcare providers treating patients with diabetic eye disease, dry eye, and neuro-ophthalmic disorders in global markets. – Following the late-May 2026 failure of its Phase 3 DIAMOND trials, Oculis is no longer pursuing FDA approval for OCS-01 in diabetic macular edema. The company is now concentrating its pipeline on two remaining registrational programs: Privosegtor (PIONEER-1, Phase 3 for optic neuropathies, which holds FDA Breakthrough Therapy Designation) and Licaminlimab (PREDICT-1, Phase 2b for dry eye disease). – As of March 31, 2026, the company reported $277.6 million in cash, cash equivalents, and short-term investments, providing a funding runway into the second half of 2029.
What this transaction means for investors Nan Fung’s Q1 trim of its Oculis stake looks less like a vote of no confidence and more like routine portfolio rebalancing. But the context around Oculis…